Emerging Nanomedicine


Currently, the treatment of HIV requires regular oral dosage of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies. Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.


    Related Conference of Emerging Nanomedicine

    December 05-06, 2022

    Applied Nanotechnology Summit

    Paris, France
    January 18-19, 2023

    Global Summit on Nanoscience and Technology

    Vancouver, Canada
    January 18-19, 2023

    3rd World Conference on Aerospace Engineering

    London, UK
    April 17-18, 2023

    35th Nano Congress for Future Advancements

    Paris, France
    May 10-11, 2023

    8th Annual Conference and Expo on Biomaterials

    Zurich, Switzerland
    June 26-27, 2023

    40th Global Summit on Nanoscience and Technology

    Tokyo, Japan
    July 05-06, 2023

    40th Global Nanotechnology Congress

    Paris, France
    August 08-09, 2023

    26th World Nanotechnology Congress

    Dublin, Ireland
    September 27-28, 2023

    32nd International Conference on Nanomedicine & Drug Delivery

    Zurich, Switzerland
    November 08-09, 2023

    4th World Congress on Nanotechnology and Advanced Materials

    Budapest, Hungary

    Emerging Nanomedicine Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in